PHE - Corporate - A Clinical and Cost Effectiveness Model on Formalising New-born Screening for β-thalassaemia Major
Public Health Englandservices
What the buyer wrote
Commissioning document: Formalising screening for β-thalassaemia major as part of the newborn blood spot screening programme for sickle cell disease: a clinical and cost-effectiveness model
Bid for this and lost? There is a short window in which the decision can be questioned.
Awarded to
Details
- What the buyer calls it
- PHE - Corporate - A Clinical and Cost Effectiveness Model on Formalising New-born Screening for β-thalassaemia Major
- How they are buying
- Called off an existing agreementThe work went to a supplier already on a framework or dynamic market.
- Type
- services
- Suitable for small firms
- The buyer says yes. What that is worth
- Work starts
- 2 Nov 2020
- Work ends
- 29 Apr 2022
Who the buyer named
Sandeep Kapoor was the named contact on this notice.